Biopharma · FDA Approvals · Stock

AUPH Aurinia

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is als…

Assets on file: voclosporin

Start live analysis of AUPH Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for AUPH, including recently decided ones.

June 2027

Jun 2027

~ Jun 2027

AUPHAurinia

voclosporin: Phase 3 trial NCT06406205 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for AUPH, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Aug 19, 2026

08:11 PM

AUPHAurinia

Aurinia settles patent litigation with Teva over generic voclosporin

Aurinia and Teva entered a settlement agreement resolving patent infringement litigation. Teva stipulated that Aurinia's U.S. Patent Nos. 10,286,036 and 11,622,991 are valid and enforceable. Teva may launch its generic voclosporin product no earlier than December 7, 2036, subject to FDA approval.

OtherSEC 8-K